** Shares of Vir Biotechnology VIR.O slip 5.2% to $9 post-market as it looks to raise equity after its stock soared in regular session

** VIR shares finished up 27.7% at $9.49 on Tues after co posted Q4 results beat and said plans to develop and commercialize its prostate cancer experimental drug with Japan's Astellas 4503.T

** San Francisco, California-based VIR announces $200 mln stock offering after the bell

** Goldman Sachs, Leerink, Evercore and Barclays joint bookrunners

** Co has ~139.5 mln shares outstanding for about $1.3 bln market cap

** All 10 analysts are bullish on VIR; median PT $17, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))